Prime Therapeutics Completes $1.35B Deal to Acquire Magellan Rx

December 6th 2022

Magellan Rx's businesses includes a 1.7-million member PBM. The deal is struck amid a long-time trend toward consolidation in the pharmacy benefit management industry.

ICER: Drugs with Unsupported Price Increases Added $805 Million in Costs

December 6th 2022

Seven of the 10 top selling drugs with high price increases lack the clinical evidence to justify those increases.

Anti-Tau Alzheimer’s Treatment Slows Cognitive Decline

December 6th 2022

TauRx’s oral anti-tau therapy HMTM has shown in a phase 3 trial that it can stabilize cognitive decline in patients with Alzheimer’s disease.

Cigna, Express Scripts to Provide Humira Biosimilars as Preferred Products

December 5th 2022

Cigna and Express Scripts have not yet made a decision about which of the Humira biosimilars will be included but they will evaluate all products in the coming months.

FDA Accepts Resubmitted BLA for Fabry Disease

December 5th 2022

A Prescription Drug User Fee Act action date for pegunigalsidase alfa is set for May 9, 2023.